Brief: HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies
14/05/2026 12:32
May 14 (Reuters) - HCW Biologics Inc HCWB.O: HCW BIOLOGICS DISCOVERS THAT HCW11-040 PREVENTS BRONCHOPULMONARY DYSPLASIA (BPD) DURING IND-ENABLING STUDIES HCW BIOLOGICS INC - EXPECTS TO COMPLETE IND-ENABLING STUDIES IN H2 2027 AND FILE IND APPLICATION FOR HCW11-040 Source text: ID:nGNX7jwMkY Further company coverage: HCWB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM